Development of a Novel HEK293 Cell Model Lacking SLC29A1 to Study the Pharmacology of Endogenous SLC29A2 -Encoded Equilibrative Nucleoside Transporter Subtype 2.

MLA

Shahid, Nayiar, et al. “Development of a Novel HEK293 Cell Model Lacking SLC29A1 to Study the Pharmacology of Endogenous SLC29A2 -Encoded Equilibrative Nucleoside Transporter Subtype 2.” Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 52, no. 10, Sept. 2024, pp. 1094–103. EBSCOhost, https://doi.org/10.1124/dmd.124.001814.

APA

Shahid, N., Cromwell, C., Hubbard, B. P., & Hammond, J. R. (2024). Development of a Novel HEK293 Cell Model Lacking SLC29A1 to Study the Pharmacology of Endogenous SLC29A2 -Encoded Equilibrative Nucleoside Transporter Subtype 2. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 52(10), 1094–1103. https://doi.org/10.1124/dmd.124.001814

Chicago

Shahid, Nayiar, Christopher Cromwell, Basil P Hubbard, and James R Hammond. 2024. “Development of a Novel HEK293 Cell Model Lacking SLC29A1 to Study the Pharmacology of Endogenous SLC29A2 -Encoded Equilibrative Nucleoside Transporter Subtype 2.” Drug Metabolism and Disposition: The Biological Fate of Chemicals 52 (10): 1094–1103. doi:10.1124/dmd.124.001814.